18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in a Patient with HIV (-) Kaposi Sarcoma

Cengiz, Arzu; Şavk, Ekin; Tataroğlu, Canten; Yürekli, Yakup

doi:10.4274/mirt.07078

Cited by 4 publications

(4 citation statements)

References 10 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limited published data are available on the DA of FDG PET/CT in KS. Some case series suggested the efficacy of FDG PET/CT for KS staging, with FDG-avid lesions identified in the skin, lymph nodes, as well as occult visceral locations [17,19,[24][25][26], and for follow-up during treatment [18,27,28]. Our study confirmed some of these preliminary data in a large population.…”

Section: Discussionsupporting

confidence: 84%

“…FDG PET/CT can provide a whole-body assessment of a proliferative or inflammatory disease, delivering metabolic and morphologic information concomitantly. Some cases of patients with KS successfully assessed with FDG PET/CT were reported, suggesting that it may be a useful tool to assess KS extension or treatment response [17][18][19][20][21][22]. However, no study measuring the efficacy of FDG PET/CT in KS has been reported to date.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma

Pesqué

Delyon

Lheure

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Positron emission tomography/computed tomography with fluorodeoxyglucose (F-18) (FDG PET/CT) is increasingly used in Kaposi sarcoma (KS), but its value has not been assessed. Objectives: In this study, we aimed to evaluate the diagnostic accuracy of FDG PET/CT to define the extent of disease in KS. Methods: Consecutive patients with KS referred to our department for FDG PET/CT were included. The diagnostic accuracy of FDG PET/CT for cutaneous and extra-cutaneous KS staging was assessed on a per lesion basis compared to staging obtained from clinical examination, standard imaging, endoscopy, histological analyses, and follow-up. Results: From 2007 to 2017, 75 patients with FDG PET/CT were analyzed. The sensitivity and specificity of FDG PET/CT for the overall detection of KS lesions were 71 and 98%, respectively. Sensitivity and specificity were 100 and 85% for lymph nodes, 87 and 98% for bone, 87 and 100% for lungs, and 100 and 100% for muscle involvement, whereas sensitivity was only 17% to detect KS digestive involvement. The sensitivity of the diagnostic for KS cutaneous involvement increased from 73 to 88% when using a whole-body examination. Conclusion: FDG PET/CT showed good sensitivity and specificity for KS staging (digestive involvement excepted) and could be used for staging patients with active KS.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma

Pesqué

Delyon

Lheure

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Skin uptake can be focal or diffuse and is more commonly seen in the legs and lower torso. In addition, it can help distinguish visceral or skeletal involvement [56], which can portend a worse prognosis. KS is a widespread disease that can be occult and can affect essentially every organ; and 18 F-FDG-PET/CT scans can be beneficial for whole-body staging [57] (Fig.…”

Section: Imaging Of Kaposi Sarcoma Using Pet/ctmentioning

confidence: 99%

Imaging of Kaposi sarcoma

2021

View full text Add to dashboard Cite

show abstract

“…FDG-avid KS lesions have been reported in the skin [ 58 , 59 , 62 , 64 , 67 , 68 , 69 ], lymph nodes [ 59 , 62 , 63 , 64 , 65 , 66 , 67 ], bone [ 61 , 64 , 67 ], lungs [ 59 , 61 , 62 ], gastro-intestinal tract [ 60 ], mouth [ 66 ], thyroid [ 66 ], and salivary glands [ 64 ], which demonstrates the ability of FDG-PET to detect KS lesions in various organs. Interestingly, for some of these authors, FDG-PET was instrumental in detecting unsuspected KS lesions [ 61 , 62 , 66 ].…”

Section: Fdg-petmentioning

confidence: 99%

Current and Future Tools for Diagnosis of Kaposi’s Sarcoma

Dupin

Jary

Boussouar

et al. 2021

Cancers

View full text Add to dashboard Cite

Kaposi’s sarcoma (KS) is a rare, atypical malignancy associated with immunosuppression and can be qualified as an opportunistic tumor, which responds to immune modulation or restoration. Four different epidemiological forms have been individualized (AIDS-related, iatrogenic, endemic or classic KS). Although clinical examination is sufficient to diagnose cutaneous lesions of KS, additional explorations are necessary in order to detect lesions involving other organs. New histological markers have been developed in recent years concerning the detection of HHV-8 latent or lytic proteins in the lesions, helping to confirm the diagnosis when it is clinically doubtful. More recently, the evaluation of the local immune response has also been shown to provide some guidance in choosing the appropriate therapeutic option when necessary. We also review the indication and the results of conventional radiological imaging and of non-invasive imaging tools such as 18F-fluoro-deoxy-glucose positron emission tomography, thermography and laser Doppler imaging for the diagnosis of KS and for the follow-up of therapeutic response in patients requiring systemic treatment.

show abstract

18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in a Patient with HIV (-) Kaposi Sarcoma

Cited by 4 publications

References 10 publications

Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma

Yield of FDG PET/CT for Defining the Extent of Disease in Patients with Kaposi Sarcoma

Imaging of Kaposi sarcoma

Current and Future Tools for Diagnosis of Kaposi’s Sarcoma

Contact Info

Product

Resources

About